Predicting Response to Cholinesterase Inhibitors in Alzheimer’s Disease: Possible Approaches

Lon S. Schneider, Martin R. Farlow

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

Cholinesterase inhibitors have been more extensively investigated for the treatment of Alzheimer’s disease than other medications. Currently, tacrine is the only Cholinesterase inhibitor that is approved for marketing in the US, Australia and several European countries. Other Cholinesterase inhibitors that are currently in phase II and III clinical trials are likely to become available in the next few years. Although these agents have not been as effective as originally expected, they modestly improve cognitive function and functional activities in a subset of patients with Alzheimer’s disease. Potential predictors or response modifiers to Cholinesterase inhibitors include demographic, clinical and biological characteristics of patients. The most impressive determinants of clinical response seem to be sufficient dosage, plasma concentrations and Cholinesterase inhibition, or the effect on the CNS as indicated by elec troencephalography, cerebral blood flow or positron emission tomography (PET). At present, the best approach to the early prediction of response is to treat patients with adequate doses of Cholinesterase inhibitor, and to assess for early response within 4 weeks of instituting adequate dosage. However, there is no published basis for withholding medication from a patient because he or she is deemed to have a poor probability of response.

Original languageEnglish (US)
Pages (from-to)114-124
Number of pages11
JournalCNS Drugs
Volume4
Issue number2
DOIs
StatePublished - Aug 1995

Fingerprint

Cholinesterase Inhibitors
Alzheimer Disease
Cerebrovascular Circulation
Tacrine
Phase III Clinical Trials
Phase II Clinical Trials
Cholinesterases
Marketing
Positron-Emission Tomography
Cognition
Electroencephalography
Demography

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Predicting Response to Cholinesterase Inhibitors in Alzheimer’s Disease : Possible Approaches. / Schneider, Lon S.; Farlow, Martin R.

In: CNS Drugs, Vol. 4, No. 2, 08.1995, p. 114-124.

Research output: Contribution to journalReview article

@article{2fe1d7d5eb9941ab8b7c5f14c016dad8,
title = "Predicting Response to Cholinesterase Inhibitors in Alzheimer’s Disease: Possible Approaches",
abstract = "Cholinesterase inhibitors have been more extensively investigated for the treatment of Alzheimer’s disease than other medications. Currently, tacrine is the only Cholinesterase inhibitor that is approved for marketing in the US, Australia and several European countries. Other Cholinesterase inhibitors that are currently in phase II and III clinical trials are likely to become available in the next few years. Although these agents have not been as effective as originally expected, they modestly improve cognitive function and functional activities in a subset of patients with Alzheimer’s disease. Potential predictors or response modifiers to Cholinesterase inhibitors include demographic, clinical and biological characteristics of patients. The most impressive determinants of clinical response seem to be sufficient dosage, plasma concentrations and Cholinesterase inhibition, or the effect on the CNS as indicated by elec troencephalography, cerebral blood flow or positron emission tomography (PET). At present, the best approach to the early prediction of response is to treat patients with adequate doses of Cholinesterase inhibitor, and to assess for early response within 4 weeks of instituting adequate dosage. However, there is no published basis for withholding medication from a patient because he or she is deemed to have a poor probability of response.",
author = "Schneider, {Lon S.} and Farlow, {Martin R.}",
year = "1995",
month = "8",
doi = "10.2165/00023210-199504020-00004",
language = "English (US)",
volume = "4",
pages = "114--124",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Predicting Response to Cholinesterase Inhibitors in Alzheimer’s Disease

T2 - Possible Approaches

AU - Schneider, Lon S.

AU - Farlow, Martin R.

PY - 1995/8

Y1 - 1995/8

N2 - Cholinesterase inhibitors have been more extensively investigated for the treatment of Alzheimer’s disease than other medications. Currently, tacrine is the only Cholinesterase inhibitor that is approved for marketing in the US, Australia and several European countries. Other Cholinesterase inhibitors that are currently in phase II and III clinical trials are likely to become available in the next few years. Although these agents have not been as effective as originally expected, they modestly improve cognitive function and functional activities in a subset of patients with Alzheimer’s disease. Potential predictors or response modifiers to Cholinesterase inhibitors include demographic, clinical and biological characteristics of patients. The most impressive determinants of clinical response seem to be sufficient dosage, plasma concentrations and Cholinesterase inhibition, or the effect on the CNS as indicated by elec troencephalography, cerebral blood flow or positron emission tomography (PET). At present, the best approach to the early prediction of response is to treat patients with adequate doses of Cholinesterase inhibitor, and to assess for early response within 4 weeks of instituting adequate dosage. However, there is no published basis for withholding medication from a patient because he or she is deemed to have a poor probability of response.

AB - Cholinesterase inhibitors have been more extensively investigated for the treatment of Alzheimer’s disease than other medications. Currently, tacrine is the only Cholinesterase inhibitor that is approved for marketing in the US, Australia and several European countries. Other Cholinesterase inhibitors that are currently in phase II and III clinical trials are likely to become available in the next few years. Although these agents have not been as effective as originally expected, they modestly improve cognitive function and functional activities in a subset of patients with Alzheimer’s disease. Potential predictors or response modifiers to Cholinesterase inhibitors include demographic, clinical and biological characteristics of patients. The most impressive determinants of clinical response seem to be sufficient dosage, plasma concentrations and Cholinesterase inhibition, or the effect on the CNS as indicated by elec troencephalography, cerebral blood flow or positron emission tomography (PET). At present, the best approach to the early prediction of response is to treat patients with adequate doses of Cholinesterase inhibitor, and to assess for early response within 4 weeks of instituting adequate dosage. However, there is no published basis for withholding medication from a patient because he or she is deemed to have a poor probability of response.

UR - http://www.scopus.com/inward/record.url?scp=0029087595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029087595&partnerID=8YFLogxK

U2 - 10.2165/00023210-199504020-00004

DO - 10.2165/00023210-199504020-00004

M3 - Review article

AN - SCOPUS:0029087595

VL - 4

SP - 114

EP - 124

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 2

ER -